SDGR Q3 2025 Earnings Call Summary

Total Revenue: $54 million, a 54% increase year-over-year.
Software Revenue: $40.9 million, up 28% from Q3 2024, driven by hosted contracts and on-premise renewals.
Drug Discovery Revenue: $13.5 million, significantly up from $3.4 million in Q3 2024.
Net Loss: $33 million, or $0.45 per diluted share, compared to a net loss of $38 million, or $0.52 per diluted share in Q3 2024.
Cash Position: $401 million in cash and equivalents as of September 30, 2025.
Operating Expenses: Decreased by 14% to $74 million, driven by lower R&D and G&A expenses.

Continued focus on enhancing software capabilities, including the release of the 2025-4 software update and ongoing beta for predictive toxicology solutions.
Shift in strategy to not advance internal discovery programs into clinical stages independently, opting instead for partnerships to manage risk and improve profitability.
Significant progress in drug discovery collaborations, with over 25 programs advanced to development candidate stage since 2020.
Upcoming presentation of clinical data for SGR-1505 at the American Society of Hematology Conference, showcasing its potential as a best-in-class MALT1 inhibitor.

Software Revenue Growth Guidance: Revised to 8%-13% from a previous range of 10%-15% due to delays in pharma scale-up opportunities.
Drug Discovery Revenue Guidance: Increased to $49 million - $52 million, exceeding previous expectations.
Software Gross Margin: Expected to be 73%-75%.
Continued commitment to managing expenses, with expectations for lower operating expenses in 2025 compared to 2024.

The company acknowledged a slowdown in the pharmaceutical sector impacting customer discussions and the timing of new contracts.
The decision to halt independent clinical development reflects broader challenges in the biotech industry, including layoffs and company shutdowns.
The updated software revenue guidance indicates a cautious outlook amidst ongoing macroeconomic pressures.

Management emphasized that the reduction in clinical development is not a reflection of the quality of their programs but rather a strategic decision to focus on partnerships for greater efficiency and profitability.
There are encouraging signs of recovery in the biotech sector, but sustained improvement may take time.
The predictive toxicology solution is still in beta, with positive customer interest but no immediate monetization timeline.
Discussions around the Novartis partnership indicate successful collaboration and revenue generation from that relationship.
Management remains optimistic about the long-term potential of their software and drug discovery platforms, despite current industry challenges.

SDGR — Schrödinger, Inc.